GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioGaia AB (FRA:BGLA) » Definitions » Cyclically Adjusted Price-to-FCF

BioGaia AB (FRA:BGLA) Cyclically Adjusted Price-to-FCF : 53.52 (As of May. 19, 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioGaia AB Cyclically Adjusted Price-to-FCF?

As of today (2024-05-19), BioGaia AB's current share price is €11.24. BioGaia AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.21. BioGaia AB's Cyclically Adjusted Price-to-FCF for today is 53.52.

The historical rank and industry rank for BioGaia AB's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

FRA:BGLA' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 39.18   Med: 49.18   Max: 74.34
Current: 56.45

During the past years, BioGaia AB's highest Cyclically Adjusted Price-to-FCF was 74.34. The lowest was 39.18. And the median was 49.18.

FRA:BGLA's Cyclically Adjusted Price-to-FCF is ranked worse than
67.38% of 328 companies
in the Drug Manufacturers industry
Industry Median: 33.52 vs FRA:BGLA: 56.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BioGaia AB's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.038. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.21 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioGaia AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioGaia AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGaia AB Cyclically Adjusted Price-to-FCF Chart

BioGaia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.69 58.80 51.29 39.92 41.41

BioGaia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.33 51.72 43.70 41.41 53.86

Competitive Comparison of BioGaia AB's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioGaia AB's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Cyclically Adjusted Price-to-FCF falls into.



BioGaia AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioGaia AB's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=11.24/0.21
=53.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BioGaia AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.038/132.2054*132.2054
=0.038

Current CPI (Mar. 2024) = 132.2054.

BioGaia AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.021 100.432 0.028
201409 -0.019 100.161 -0.025
201412 -0.012 100.225 -0.016
201503 0.047 99.950 0.062
201506 0.030 99.995 0.040
201509 0.021 100.228 0.028
201512 0.014 100.276 0.018
201603 0.041 100.751 0.054
201606 0.014 101.019 0.018
201609 0.063 101.138 0.082
201612 0.054 102.022 0.070
201703 0.094 102.022 0.122
201706 0.015 102.752 0.019
201709 0.046 103.279 0.059
201712 0.079 103.793 0.101
201803 0.045 103.962 0.057
201806 0.031 104.875 0.039
201809 0.080 105.679 0.100
201812 0.035 105.912 0.044
201903 0.034 105.886 0.042
201906 0.024 106.742 0.030
201909 0.057 107.214 0.070
201912 0.002 107.766 0.002
202003 0.073 106.563 0.091
202006 0.034 107.498 0.042
202009 0.057 107.635 0.070
202012 0.054 108.296 0.066
202103 0.040 108.360 0.049
202106 0.054 108.928 0.066
202109 0.064 110.338 0.077
202112 0.051 112.486 0.060
202203 0.083 114.825 0.096
202206 0.073 118.384 0.082
202209 0.039 122.296 0.042
202212 0.083 126.365 0.087
202303 0.086 127.042 0.089
202306 0.068 129.407 0.069
202309 0.075 130.224 0.076
202312 0.095 131.912 0.095
202403 0.038 132.205 0.038

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioGaia AB  (FRA:BGLA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioGaia AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioGaia AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioGaia AB (FRA:BGLA) Business Description

Industry
Traded in Other Exchanges
Address
Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.

BioGaia AB (FRA:BGLA) Headlines

No Headlines